Clinical trials for treating patients with non-small-cell lung cancer, renal cell carcinoma, and B and T Hodgkin’s lymphoma by using anti-PD-1 mAb rather than conventional therapy showed enhanced clinical benefit, with improvements in overall and progression-free survival [20]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.